Section 4 of Chapter 52 of the Acts of 2016, An Act relative to substance use, treatment, education and prevention, amends section 13 of chapter 17 of the General Laws to require the Drug Formulary Commission, by September 1, 2016, to publish, distribute, and update annually a list of FDA approved, non-opioid drug products that are effective pain drug products management alternatives and have a lesser potential for abuse than Schedule II and III opioid drug products.
This list is intended for informational purposes only and not intended to be either exhaustive or to be used as guidance for opioid substitution.